Beijing Med-Pharm Corporation (BJGP.PK) today announced that Fred M. Powell will serve as Chief Financial Officer.
PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--April 6, 2005--Beijing Med-Pharm Corporation (BJGP.PK) today announced that Fred M. Powell will serve as Chief Financial Officer.
Mr. Powell comes to Beijing Med-Pharm from EXIMIAS Pharmaceutical Corporation where he served as Chief Financial Officer and completed a $63.5 million private financing in 2004. Mr. Powell also served as Chief Financial Officer at Premier Research Worldwide at the time of their initial public offering.
"We are very pleased to bring on board a top-notch financial executive such as Fred Powell," says Martyn Greenacre, Chairman of Beijing Med-Pharm. "Fred has had considerable experience working with emerging life science companies and with the financial community. He's an excellent fit for our needs."
"I am excited to join the Beijing Med-Pharm team and look forward to helping the company during what I hope to be a time of considerable growth," said Mr. Powell. Mr. Powell joins Beijing Med-Pharm with more than 20 years of public accounting and corporate finance experience.
From 2002-2004, he served as Chief Financial Officer of EXIMIAS Pharmaceutical Corporation, a pharmaceutical company that develops novel oncology products.
Mr. Powell worked at InnaPhase Corporation from 1999-2002 as Senior Vice President, Finance and Administration. During his tenure, InnaPhase completed two private financings as well as an acquisition of a pharmaceutical software business.
Mr. Powell served from 1993-1999 at Premier Research Worldwide, a leading contract research organization to the pharmaceutical industry. As Chief Financial Officer, Mr. Powell helped Premier complete its initial public offering and several acquisitions including that of DLB, a clinical trial and data management software company.
Mr. Powell spent six years at KPMG Peat Marwick as a senior manager responsible for directing the planning, coordination and delivery of audit management and technology services to clients in the pharmaceutical and services industries.
Mr. Powell graduated from Penn State University with a Bachelor of Science in Accounting and is a Certified Public Accountant.
About Beijing Med-Pharm
Beijing Med-Pharm Corporation (www.beijingmedpharm.com) is a Delaware corporation with subsidiary pharmaceutical marketing operations in China. Beijing Med-Pharm's services include pre-market entry analysis; market research; clinical trial management; product registration; and pharmaceutical marketing to physicians, hospitals, and other healthcare providers. For more information, contact Ben Austin at 917-686-3979 or baustin@beijingmedpharm.com .
# # #
Beijing Med-Pharm Corp. has filed a registration statement with the Securities and Exchange Commission relating to the sale of its common stock. This registration statement has not yet become effective. The securities covered by the registration statement may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Using Patient Reported Outcomes in Dermatology Trials
April 25th 2024In part 3 of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA sheds light on the unique challenges of dermatology trials and how clinical outcome assessments can be implemented in them.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.